MK-677 (Ibutamoren) — mechanism, evidence, and research applications

At 25 your body produces growth hormone in amounts that maintain muscle, repair tissue, and deliver deep, restorative sleep. At 40 that production has halved. At 60 — it has dropped to a quarter. This is not a disease. It is physiology: each decade the pituitary releases less GH, and the consequences ripple through body composition, sleep quality, bone density, and repair capacity. For decades the only way to “top it up” was recombinant growth hormone — injections that cost a fortune and carried a load of side-effect risk. Then MK677 arrived: an oral molecule that does not deliver growth hormone from outside, but “asks” the pituitary to make it itself.

This article is educational and reviews the published scientific literature. The studies described were conducted in animal models or in vitro unless stated otherwise. This is not medical advice.

What MK-677 is, and how it was discovered

MK-677, also known as Ibutamoren, is an oral ghrelin mimetic — ghrelin being the “hunger hormone” produced mainly in the stomach. It was developed by Merck & Co. in the 1990s as a potential treatment for growth hormone deficiency, sarcopenia, and osteoporosis.

An important distinction: MK-677 is not a SARM. It does not bind the androgen receptor and does not modulate androgenic signaling. It is sometimes grouped with SARMs in research-reagent catalogs for classification convenience, but its mechanism is entirely different. MK-677 is a growth hormone secretagogue — a substance that stimulates endogenous (the body’s own) GH production.

Ghrelin — the “hunger hormone” — beyond appetite regulation also stimulates growth hormone release. When ghrelin binds the GHS-R1a receptor in the pituitary, the pituitary releases GH into the bloodstream. MK-677 mimics that signal — it binds the same receptor and triggers GH release, without delivering exogenous hormone.

More on the SARM and modulator context is available in the overview article: What SARMs are: mechanism, generations, and the state of the research.

Mechanism of action — the ghrelin receptor and the GH/IGF-1 axis

The somatotropic axis (GH/IGF-1) is the hormonal system responsible for growth, repair, and metabolism. It works like a chain of command:

1. The hypothalamus releases GHRH (growth hormone-releasing hormone) — the “produce GH” signal
2. The pituitary responds to GHRH by releasing GH into the blood
3. The liver, under GH stimulation, produces IGF-1 — a growth factor that reaches muscle, bone, and other tissues
4. Somatostatin (from the hypothalamus) inhibits the whole process — the “brake” that prevents overproduction

MK-677 plugs into this chain at the pituitary level, mimicking ghrelin. The effect? The pituitary releases GH in pulses — in a pattern close to the natural rhythm of secretion. That is a meaningful difference from exogenous GH (injections), which delivers a steady level of hormone, bypassing the physiological pulse.

The best analogy: exogenous GH is power from a backup generator — it works, but not in the way the wiring is designed for. MK677 is fixing the switch in the breaker panel — power flows from the grid (the pituitary), through the normal circuit, in the normal cycles.

The effects of pulsatile GH rise and the secondary IGF-1 rise observed in studies include:

• Increased protein synthesis in skeletal muscle
• Improved bone mineralization (long-term)
• Improved sleep quality (GH is released mainly during deep sleep)
• Effects on adipose-tissue metabolism (lipolysis)
• Increased nitrogen retention (positive nitrogen balance = anabolic conditions)

What the science says

MK-677 stands out in its category with a relatively rich evidence base — including human clinical trials.

Nass et al. (2008) — older adults, body composition, GH levels

A randomized, placebo-controlled study published in Annals of Internal Medicine. 65 healthy adults aged 60–81 received MK-677 (25 mg/day) or placebo for 12 months. Results: MK-677 increased GH and IGF-1 levels to values seen in healthy young adults. An increase in fat-free mass (FFM) was recorded, without a significant change in fat mass. Increases in fasting glucose and insulin were also noted — indicating a potential impact on insulin sensitivity.

This is a human clinical study — one of the strongest entries in the MK-677 literature.

Murphy et al. (1998) — nitrogen balance and GH secretion

A short-term study in healthy volunteers showed that MK-677 at 25 mg/day for 7 days reversed the negative nitrogen balance induced by caloric restriction. This effect suggests anti-catabolic properties — the capacity to protect muscle from breakdown under energy deficit. GH secretion increased by about 40% versus placebo.

Copinschi et al. (1997) — sleep and sleep architecture

One of the most intriguing MK-677 studies concerns its effect on sleep. Copinschi and colleagues showed that MK-677 lengthens REM sleep and slow-wave sleep (SWS) duration in healthy young men. The effect is consistent with physiology: GH is released mainly during deep sleep, and MK-677’s stimulation of the GH axis amplifies that natural mechanism.

For researchers in chronobiology and neuroendocrinology, this aspect of MK-677 — its effect on sleep architecture — is a distinct, fascinating line of exploration.

Interested in research reagents for studies on the GH/IGF-1 axis? Check MK-677 in the One-Peptides catalog — every batch with an HPLC certificate of analysis.

MK-677 and sleep — effects on sleep architecture

The Copinschi data deserve their own section, because they represent a unique point in the MK-677 research profile.

Slow-wave sleep (SWS) is the phase during which most repair processes happen: from muscle recovery, through memory consolidation, to “metabolite cleanup” in the brain (the glymphatic system). With age the proportion of slow-wave sleep declines — a 50-year-old spends about 60% less time in SWS than a 25-year-old.

MK-677, by stimulating pulsatile GH release, reinforces the natural nocturnal peak of growth hormone secretion. Studies have shown:

• Extension of stage IV sleep (deep sleep) by about 50%
• Extension of REM by about 20%
• Shorter sleep latency (time to fall asleep)

This is not a sleep-inducing effect in the classical sense — MK-677 does not act as a hypnotic. In polysomnographic studies it was associated with changes in sleep architecture: longer REM sleep and, in younger participants, longer deep (stage IV) sleep.

Potential adverse effects in light of the research

No substance is free of potential adverse effects. For MK-677, clinical trials observed the following:

• Appetite increase — consistent with the ghrelin mechanism. MK-677 mimics ghrelin, and ghrelin is the hunger hormone. Most participants reported increased appetite, particularly in the first weeks.
• Water retention — mild edema, particularly peripheral (hands, feet). An effect linked to GH and antidiuretic activity.
• Fasting glucose and insulin increase — observed in Nass et al. (2008). Reduced insulin sensitivity was the main metabolic safety signal in the clinical studies of MK-677.
• Paresthesias (tingling) — occasionally reported, particularly in the hands. Linked to water retention and nerve compression (a mechanism similar to carpal tunnel).
• Lethargy and sleepiness — some participants reported sleepiness, which may relate to the sleep-architecture effects.

The MK-677 safety profile in studies up to 12 months appears moderately favorable compared with exogenous GH. There are, however, no multi-year data.

MK-677 vs other secretagogues — how it differs from exogenous GH and GHRP

A detailed comparison of MK677 with HGH Fragment 176-191 — a lipolytic peptide that is a fragment of growth hormone — is covered in the article: MK-677 vs HGH Fragment — comparing the mechanisms.

Running research on growth hormone secretagogues? One-Peptides offers MK-677 and peptides from the GHRP family (including GHRP-2 and GHRP-6) — all with an HPLC certificate confirming purity ≥98%.

Summary

• MK677 (Ibutamoren) is an oral ghrelin mimetic — a growth hormone secretagogue, not a SARM
• It binds the GHS-R1a receptor in the pituitary, stimulating pulsatile GH release and IGF-1 elevation
• Human clinical trials (Nass et al., 2008) showed GH/IGF-1 increases to levels seen in young adults
• Unique feature: improved sleep architecture — extended slow-wave sleep (SWS) and REM
• Main adverse effects in trials: appetite increase, water retention, potential impact on insulin sensitivity
• Safety profile in trials up to 12 months moderately favorable, no multi-year data
• Oral route — an advantage over injectable GHRPs and exogenous GH in terms of convenience

More articles from this cluster: SARMs & modulators category.

References

1. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003
2. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325. doi:10.1210/jcem.83.2.4551
3. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-286. doi:10.1159/000127249
4. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. doi:10.1210/jcem.81.12.8954023
5. Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346-360. doi:10.1210/er.2004-0019

MK-677 is not a SARM, but it is often discussed alongside SARMs — see how SARMs work.

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›